InvivoCrown In vivo CTLA-4 neu

InVivoPro Anti-Mouse CTLA-4 (CD152) in vivo antibody, Clone 9D9InVivoPro Anti-Mouse CTLA-4 (CD152) in vivo antibody, Clone 9D9Mouse IgG2bMouse IgG2b9D99D9CTLA-4CTLA-4CD152, Cytotoxic T Lymphocyte-Associated Antigen-4, Ly-56CD152, Cytotoxic T Lymphocyte-Associated Antigen-4, Ly-56Mouse IgG2b Isotype ControlMouse IgG2b Isotype ControlPBS, pH 7.2, contains no stabilizers or preservativesPBS, pH 7.2, contains no stabilizers or preservativesMouseMouseMouseMouse200-500 μg per mouse; or 10-20 mg/kg. This range is based off the most recent publication data using the 9D9 clone in vivo. Each investigator should determine their own optimal working dilution for specific applications.200-500 μg per mouse; or 10-20 mg/kg. This range is based off the most recent publication data using the 9D9 clone in vivo. Each investigator should determine their own optimal working dilution for specific applications.152152Sade-Feldman, Moshe et al. "Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma",Cell 175.4 (2018): 998-1013.e20. Benci, Joseph L. et al. "Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade",Cell 178.4 (2019): 933-948.e14. Cappellesso, Federica et al. "Targeting the Bicarbonate Transporter SLC4A4 Overcomes Immunosuppression and Immunotherapy Resistance in Pancreatic Cancer",Nature cancer 3.12 (2022): 1464-1483.Sade-Feldman, Moshe et al. "Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma",Cell 175.4 (2018): 998-1013.e20. Benci, Joseph L. et al. "Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade",Cell 178.4 (2019): 933-948.e14. Cappellesso, Federica et al. "Targeting the Bicarbonate Transporter SLC4A4 Overcomes Immunosuppression and Immunotherapy Resistance in Pancreatic Cancer",Nature cancer 3.12 (2022): 1464-1483.CTLA-4 is a 33 kD member of the Ig superfamily similar to CD28 in amino acid sequence, structure, and genomic organization. CTLA-4 is a protein receptor that functions as an immune checkpoint and downregulates immune responses. It is involved in the development of protective immunity and thymocyte regulation, in addition to the induction and maintenance of immunological tolerance. CTLA-4 has therapeutic potential both as an agonist to reduce immune activity, and an antagonist to increase immune activity.CTLA-4 is a 33 kD member of the Ig superfamily similar to CD28 in amino acid sequence, structure, and genomic organization. CTLA-4 is a protein receptor that functions as an immune checkpoint and downregulates immune responses. It is involved in the development of protective immunity and thymocyte regulation, in addition to the induction and maintenance of immunological tolerance. CTLA-4 has therapeutic potential both as an agonist to reduce immune activity, and an antagonist to increase immune activity.In vivo CTLA-4 neutralization, Western blotIn vivo CTLA-4 neutralization, Western blotprotein A or Gprotein A or GThis antibody is stable for at least 2 months when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at -20°C or -80°C. Avoid repeated freeze thaw cycles.This antibody is stable for at least 2 months when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at -20°C or -80°C. Avoid repeated freeze thaw cycles.2-8°C with blue ice2-8°C with blue iceLot specific, generally ≥ 5.0 mg/mlLot specific, generally ≥ 5.0 mg/ml12 months from the date of receipt if stored as recommended12 months from the date of receipt if stored as recommendedPBS Buffer, PH 7.2, with no carrier protein, or preservatives.PBS Buffer, PH 7.2, with no carrier protein, or preservatives.0.2 μM filtered0.2 μM filtered≤ 1.0 EU/mg, by the LAL method≤ 1.0 EU/mg, by the LAL method0.990.99可替换BioXCell产品货号为BE0164